The collaboration, which was announced last week, is between Bicycle Health, Wellpath and the Federal Bureau of Prisons. It will provide virtual opioid use disorder services to those living in the Bureau's residential reentry centers in 42 states.
The Covid-19 public health emergency waived a rule that required a practitioner to conduct an in-person medical exam before prescribing controlled substances via telemedicine. Once the public health emergency ends on May 11, those with substance use disorder could be greatly affected, experts are warning.
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
Protectionism against (and fear of) telehealth on display from companies like Walmart and states like Alabama threaten the only effective and scalable solution to America’s opioid epidemic.
EmpiRx found in its data that pharmacy claims for behavioral health treatments increased 9.4% from 2020 to 2021. For antidepressants, utilization increased 12% during this time period, but per claim spend fell 1.8%. ADHD medications saw a 20.2% increase in utilization and a 9.1% decrease in per claim spend.
Over 1 million Medicare beneficiaries had a diagnosis for opioid use disorder in 2021. But despite this high number, only 18% received medication to treat their disorder.
Bicycle Health provides medication for addiction treatment. Through its telehealth platform, it also offers a team of medical experts, a customized treatment plan, same-day prescription refills for medication management, peer support groups and therapy.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
Medications that treat opioid use disorder (OUD) — such as methadone, buprenorphine and extended-release naltrexone — are proven to save lives. However, a new study revealed that less than 15% of Americans with OUD receive these medications. Its lead author laid out three actions the U.S. should prioritize to increase access.
The startup began with digital tobacco cessation programs, but recently expanded to programs for alcohol use disorder and opioid use disorder. The $64 million funding round was led by Kinnevik and Atomico.
Most apps offering opioid use disorder treatment have access to sensitive identifying information of their users, according to an analysis of 10 of them.
Temporary policy changes during the Covid-19 pandemic let people access substance use treatment over telehealth for the first time. Now, healthcare providers and policymakers are watching legislation that would allow patients to continue to access these services virtually.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
In a review of real-world claims data, Pear Therapeutics found that its digital therapeutic for opioid use disorder resulted in a reduction in spending $2,150 per patient over six months.
Recently, the San Francisco-based health plan reported positive results that showed a 56 percent reduction in overall opioid use among members with chronic, non-cancer pain from 2014 levels.
The reSET-O prescription mobile application is directed at supporting patients using buprenorphine as a medicinal aid in treatment to overcome opioid addiction.